Your browser doesn't support javascript.
loading
Case Report: Refusal of an Veno-Arterial Extracorporeal Membrane Oxygenation Due to Malignant Disease? - An Extremely Rare Form of Cardiac Involvement in Acute Myeloid Leukemia.
Zotzmann, Viviane; Wengenmayer, Tobias; Lang, Corinna N; Staudacher, Dawid L; Mueller-Peltzer, Katharina; Bamberg, Fabian; Marks, Reinhard; Bode, Christoph; Wäsch, Ralph.
Afiliação
  • Zotzmann V; Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
  • Wengenmayer T; Department of Cardiology and Angiology I, University Heart Center Freiburg, Bad Krozingen, Germany.
  • Lang CN; Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
  • Staudacher DL; Department of Cardiology and Angiology I, University Heart Center Freiburg, Bad Krozingen, Germany.
  • Mueller-Peltzer K; Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
  • Bamberg F; Department of Cardiology and Angiology I, University Heart Center Freiburg, Bad Krozingen, Germany.
  • Marks R; Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
  • Bode C; Department of Cardiology and Angiology I, University Heart Center Freiburg, Bad Krozingen, Germany.
  • Wäsch R; Department of Diagnostic and Interventional Radiology, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
Front Med (Lausanne) ; 8: 584507, 2021.
Article em En | MEDLINE | ID: mdl-33708776
ABSTRACT
We report here on a 61-year-old patient with acute right heart failure of unclear etiology. Echocardiography revealed a myocardial mass infiltrating the heart, though, we assumed a cardiac lymphoma. A VA-ECMO was implanted as bridging for diagnosis and therapy. Our patient received chemotherapy, under which the tumor (of unknown etiology at this point) reached a partial remission. Nine months after first admission the patient developed acute myeloid leukemia with DNMT3a and TET2 mutations. Retrospective analysis of the cardiac biopsy revealed the identical mutations and matched with the diagnosis of an extremely rare primary extramedullary manifestation of an AML (myelosarcoma). The patient received induction-chemotherapy and was planned for consolidating allogeneic stem cell transplantation. From this case, we conclude that an extracorporeal therapy should be discussed in selected patients even in case of an initially fatal appearing prognosis. In selected cases, extracorporeal support can generate enough time for diagnosis and therapy. However, transparent planning, including discussion of best supportive care strategies involving the patient's family are indispensable requirements for starting ECMO in such patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Med (Lausanne) Ano de publicação: 2021 Tipo de documento: Article